From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countriesReport as inadecuate




From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries - Download this document for free, or read online. Document in PDF available to download.

Health Research Policy and Systems

, 13:39

First Online: 25 September 2015Received: 07 October 2014Accepted: 07 September 2015DOI: 10.1186-s12961-015-0028-5

Cite this article as: Panteli, D., Eckhardt, H., Nolting, A. et al. Health Res Policy Sys 2015 13: 39. doi:10.1186-s12961-015-0028-5

Abstract

BackgroundCoverage decisions determining the benefit baskets of health systems have been increasingly relying on evidence regarding patient benefit and costs. Relevant structures, methodologies, and processes have especially been established for pharmaceuticals but approaches differ. The objective of this work was thus to identify institutions in a broad range of European countries n = 36 in charge of determining the value of pharmaceuticals for pricing and reimbursement purposes and to map their decision-making process; to examine the different approaches and consider national and supranational possibilities for best practice.

MethodsInstitutions were identified through websites of international networks, ministries, and published literature. Details on institutional practices were supplemented with information from institution websites and linked online sources.

ResultsThe type and extent of information available varied considerably across countries. Different types of public regulatory bodies are involved in pharmaceutical coverage decisions, assuming a range of responsibilities. As a rule, the assessment of scientific evidence is kept structurally separate from its appraisal. Recommendations on value are uniformly issued by specific committees within or commissioned by responsible institutions; these institutions often also act as decision-makers on reimbursement status and level or market price. While effectiveness and costs are important criteria in all countries, the latter are often considered on a case-by-case basis. In all countries, manufacturer applications, including relevant evidence, are used as one of the main sources of information for the assessment.

ConclusionTransparency of evidence-based coverage decisions should be enhanced. International collaboration can facilitate knowledge exchange, improve efficiency of information production, and strengthen new or developing systems.

AbbreviationsEUEuropean Union

EUnetHTAEuropean Network for Health Technology Assessment

HTAHealth Technology Assessment

HTAiHealth Technology Assessment International

INAHTAInternational Network of Agencies for Health Technology Assessment

ISPORInternational Society For Pharmacoeconomics and Outcomes Research

Electronic supplementary materialThe online version of this article doi:10.1186-s12961-015-0028-5 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Dimitra Panteli - Helene Eckhardt - Alexandra Nolting - Reinhard Busse - Michael Kulig

Source: https://link.springer.com/







Related documents